A Bangalore-based startup, Acculi Labs has developed a mobile app for the detection and risk assessment of COVID-19 infected individuals. The app uses the potential of smartphone sensors and processors to obtain a bunch of body signals. These collected signals are then analysed to detect propensity to COVID 19.
Acculi Labs is a government-supported IT company in Bengaluru, The mobile application by Acculi Labs is capable enough to capture an individual’s vital health statistics through mobile phone to determine an individual’s propensity to COVID 19 infection. According to the ministry of science and technology, it helps in early detection of disease and risk assessment of the infected population. This innovative technology based on medical screening can identify possible infection in an asymptomatic individual, assisting him in prioritising the proper testing queue as well as in risk assessment of an asymptomatic individual to establish whether he can become symptomatic apart from assistance in risk assessment of an asymptomatic individual for recovery.
Lyfas is an Android application. When one keeps his index finger on the rear camera of a mobile phone for 5 minutes, the application captures the capillary pulse, blood volume change and procures 95 biomarkers with signal processing techniques and proprietary algorithms. Lyfas uses the power of smartphone processors and sensors to catch a bunch of body signals. The signals captured were then processed on the principle of Photo Chromatography (PCG), Photoplethysmography (PPG), Pulse Rate Variability(PRV), Arterial Photoplethysmography (APPG) and mobile spirometry. This application creates an individual’s COVID risk assessment profile called Lyfas COVID Score. Lyfas is a proper medical screening test which depends on test results. Generation of Lyfas COVID score has been accomplished through repurposing Lyfas- a clinical-grade and digital functional biomarker smartphone tool for screening and early detection, acute event risk assessment, home monitoring, root cause analysis and prognosis of chronic diseases.
Acculi Labs developed Lyfas in association with the Union government’s Centre for Augmenting WAR with Covid-19 Health Crisis (CAWACH) initiative. CAWACH supports market-ready innovations for the control of Covid-19 and startup ideas to address associated challenges. After several rounds of screening, Acculi Labs was selected for a solution towards mass screening. Lyfas has received a grant of Rs 30 Lakh from DST and is now supported virtually by IIT Madras, Healthcare Technology Innovation Centre (HTIC), MedTech Incubator.